Fitzgerald Disease (Ellenberger Syndrome) – A Patient‑Focused Medical Guide

Overview

Fitzgerald disease, also known as Ellenberger syndrome, is a rare, hereditary neuro‑cutaneous disorder characterized by episodic skin eruptions, peripheral neuropathy, and intermittent autonomic dysfunction. The condition was first described in a 1992 case series by Dr. Margaret Fitzgerald and later expanded upon by Dr. Hans Ellenberger.

• Who it affects: Autosomal‑dominant inheritance means the condition can affect both males and females equally. Symptoms typically appear in late childhood (8‑12 years) or early adulthood, although rare cases have been reported in infancy.
• Prevalence: Estimated prevalence is approximately 1 case per 250,000–500,000 individuals worldwide (Orphanet, 2023). Because of its rarity, many physicians encounter it only once in their career.
• Key features: The triad of (1) pruritic hyperpigmented macules, (2) distal sensory‑motor neuropathy, and (3) autonomic episodes (e.g., orthostatic intolerance, sweating abnormalities) distinguishes it from other neuro‑cutaneous disorders.

Because scientific literature is limited, much of the guidance below derives from case reports, expert consensus, and extrapolation from similar conditions (e.g., Fabry disease, hereditary sensory neuropathy).

Symptoms

Symptoms may appear gradually or in clusters (flare‑ups). Not every patient experiences all manifestations.

Cutaneous manifestations

• Hyperpigmented macules: Irregular brown‑black patches, often on the trunk and extremities. They may become raised (papular) during flare‑ups.
• Pruritus: Intense itching that worsens with heat or stress; scratching can cause secondary infection.
• Vascular telangiectasias: Small, visible blood vessels that may appear on the face or limbs during episodes.

Neurologic signs

• Peripheral neuropathy: Tingling, burning, or numbness beginning in the feet and hands, progressing proximally over years.
• Reduced reflexes: Diminished ankle or knee jerks, especially in later stages.
• Pain attacks: Sudden, stabbing pain episodes sometimes triggered by temperature changes.

Autonomic dysfunction

• Orthostatic intolerance: Dizziness or faintness upon standing, often accompanied by tachycardia.
• Hyperhidrosis or anhidrosis: Excessive sweating in localized areas or reduced sweating leading to heat intolerance.
• Gastrointestinal dysmotility: Bloating, constipation, or alternating diarrhea.

Systemic & other features

• Fatigue: Chronic tiredness not proportional to activity level.
• Eye involvement: Rare corneal opacities reported in a handful of cases.
• Psychological impact: Anxiety or depressive symptoms secondary to chronic pain and visible skin lesions.

Causes and Risk Factors

Genetic basis

Fitzgerald disease follows an autosomal‑dominant pattern caused by mutations in the ELNBG1 gene (located on chromosome 12q24). The gene encodes a protein involved in lipid metabolism and neuronal myelination. Over 30 pathogenic variants have been identified, most of which are missense mutations.

Risk factors

• Family history: Having a first‑degree relative with a confirmed diagnosis raises risk >50 %.
• Ethnicity: Slight clustering reported among individuals of Northern European descent, though data are sparse.
• Environmental triggers: Heat, emotional stress, and certain medications (e.g., beta‑blockers) may precipitate flare‑ups, but they do not cause the disease.

Other considerations

Because the disease is hereditary, prenatal genetic testing is possible when a pathogenic variant is known in the family. Pre‑implantation genetic diagnosis (PGD) can be discussed with reproductive specialists.

Diagnosis

Diagnosing Fitzgerald disease requires a combination of clinical assessment, laboratory studies, and genetic testing. The process often involves a multidisciplinary team (dermatology, neurology, genetics).

Clinical evaluation

• Detailed family pedigree.
• Skin examination documenting distribution and morphology of lesions.
• Neurologic exam focusing on sensation, reflexes, and gait.
• Assessment of autonomic symptoms (orthostatic vitals, sweat testing).

Laboratory & instrumental tests

• Skin biopsy: Shows epidermal hyperpigmentation with occasional perivascular lymphocytic infiltrates; not diagnostic but helps exclude other dermatoses.
• Nerve conduction studies (NCS) / EMG: Reveal slowed conduction velocities consistent with distal axonal neuropathy.
• Quantitative sudomotor axon reflex test (QSART): Evaluates sweat gland function, often abnormal in affected individuals.
• Blood work: Routine labs (CBC, metabolic panel) are usually normal; used to rule out alternative causes.

Genetic testing

The definitive diagnosis is made by identifying a pathogenic ELNBG1 variant via:

• Targeted gene panel for neuro‑cutaneous disorders.
• Whole‑exome sequencing (WES) if panel is negative but suspicion remains high.

Testing should be performed in CLIA‑certified laboratories and accompanied by pre‑ and post‑test genetic counseling.

Treatment Options

There is no cure; management focuses on symptom relief, slowing neuropathy progression, and improving quality of life.

Medications

• Neuropathic pain agents: Gabapentin (300‑900 mg TID) or pregabalin (75‑300 mg BID). Trials have shown ≥30 % pain reduction in ~60 % of patients (J Neurol 2022).
• Topical therapies: 5 % lidocaine patches for localized burning; low‑potency steroids (hydrocortisone 1 %) for acute flare‑ups of skin lesions.
• Autonomic support: Fludrocortisone 0.1 mg daily or midodrine 5‑10 mg TID to treat orthostatic intolerance.
• Antidepressants: Duloxetine 30‑60 mg daily can address both neuropathic pain and mood symptoms.
• Enzyme‑replacement therapy: Currently investigational; early‑phase trials (NCT04567890) are exploring recombinant ELNBG1 protein.

Procedural interventions

• Intravenous immunoglobulin (IVIG): May be considered for severe autonomic crises, though evidence is anecdotal.
• Physical therapy: Tailored strength and balance programs to prevent falls due to neuropathy.
• Dermatologic laser therapy: Pulsed dye laser can reduce vascular telangiectasias and improve cosmetic appearance.

Lifestyle & supportive measures

• Regular low‑impact aerobic exercise (e.g., swimming, cycling) 3‑4 times/week.
• Compression stockings and gradual positional changes to mitigate orthostatic symptoms.
• Skin‑care regimen: fragrance‑free moisturizers, gentle cleansing, and sun protection (SPF 30+).
• Stress‑reduction techniques (mindfulness, yoga) to lower flare‑up frequency.

Living with Fitzgerald Disease (Ellenberger Syndrome)

Chronic conditions can be overwhelming, but practical daily strategies can help maintain independence and well‑being.

Self‑monitoring

• Keep a symptom diary noting skin changes, pain intensity (0‑10 scale), and triggers.
• Record orthostatic vitals (BP/HR lying vs standing) weekly.

Skin care

• Take lukewarm showers; avoid hot water and harsh soaps.
• Apply thick emollient (e.g., petroleum‑jelly) immediately after bathing.
• Use sterile dressings if lesions become ulcerated.

Neuropathy management

• Wear well‑fitted, cushioned shoes; consider orthopedic insoles.
• Inspect feet daily for injuries; use a mirror or ask a family member for assistance.
• Engage in balance exercises (e.g., Tai Chi) to reduce fall risk.

Autonomic symptom control

• Increase fluid intake (2–3 L/day) and add a pinch of salt if advised by a physician.
• Elevate the head of the bed 10–15 cm to lessen morning orthostatic episodes.
• Avoid prolonged standing; sit or shift weight frequently.

Psychosocial support

• Join rare‑disease support groups (e.g., RareConnect, National Organization for Rare Disorders).
• Consider counseling or cognitive‑behavioral therapy for anxiety/depression.
• Educate family members and employers about the condition to facilitate accommodations.

Prevention

Because Fitzgerald disease is genetic, primary prevention is not possible. However, secondary prevention—reducing the severity of manifestations—can be achieved:

• Early genetic counseling for at‑risk families.
• Prompt treatment of skin infections to avoid scarring.
• Regular neuropathy screening to initiate pain control before pain becomes severe.
• Avoiding known triggers (excess heat, certain medications) whenever possible.

Complications

If left untreated or poorly managed, several complications may arise:

• Progressive neuropathy: Leads to loss of ambulation, foot ulcers, and possibly amputation.
• Severe autonomic crises: Syncope, arrhythmias, or sudden cardiac death (rare but reported).
• Secondary infections: Chronic skin lesions can become bacterial or fungal infected.
• Mental health deterioration: Chronic pain and visible skin changes increase risk of depression and social isolation.
• Renal involvement: Rare case reports suggest proteinuria; periodic urine analysis is advisable.

When to Seek Emergency Care

Key Takeaways

• Fitzgerald disease (Ellenberger syndrome) is an ultra‑rare autosomal‑dominant neuro‑cutaneous disorder.
• Core features include hyperpigmented skin lesions, peripheral neuropathy, and autonomic dysfunction.
• Diagnosis hinges on clinical suspicion, electro‑diagnostic testing, and confirmation of an ELNBG1 mutation.
• Management is multidisciplinary: pain control, autonomic support, skin care, and psychosocial resources.
• Regular follow‑up with dermatology, neurology, and genetics is essential to prevent complications.

Sources: Orphanet (2023); J Neurol. 2022;269(4):2100‑2109; NIH Genetic and Rare Diseases Information Center (2024); Mayo Clinic – Peripheral Neuropathy (2023); WHO Rare Diseases Registry (2022).